| Item Type | Name |
|
Concept
|
Liver Cirrhosis, Experimental
|
|
Concept
|
Liver Cirrhosis, Alcoholic
|
|
Concept
|
Liver Cirrhosis
|
|
Academic Article
|
TT-virus infection in North American blood donors, patients with fulminant hepatic failure, and cryptogenic cirrhosis.
|
|
Academic Article
|
Hepatitis G virus infection in patients transplanted for cryptogenic cirrhosis: red flag or red herring?
|
|
Academic Article
|
The utility of Lens culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population.
|
|
Academic Article
|
Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review.
|
|
Academic Article
|
Response to Fibrosis progression in patients treated for hepatitis C recurrence.
|
|
Academic Article
|
Liver transplantation for cryptogenic cirrhosis.
|
|
Academic Article
|
Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease.
|
|
Academic Article
|
Branched chains revisited.
|
|
Academic Article
|
Clinical significance of TT virus infection in patients with chronic hepatitis C.
|
|
Academic Article
|
Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C.
|
|
Academic Article
|
Branched-chain amino acid-enriched supplements as therapy for liver disease: Rasputin lives.
|
|
Academic Article
|
Comparative allograft histology after liver transplantation for cryptogenic cirrhosis, alcohol, hepatitis C, and cholestatic liver diseases.
|
|
Academic Article
|
Origin of adenocarcinoma in a transplanted liver determined by microsatellite analysis.
|
|
Academic Article
|
Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease.
|
|
Academic Article
|
Branched-chain amino-acid granules: can they improve survival in patients with liver cirrhosis?
|
|
Academic Article
|
Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients.
|
|
Academic Article
|
Branched-chain amino acid enriched supplements as therapy for liver disease.
|
|
Academic Article
|
Cirrhosis and liver failure in nonalcoholic fatty liver disease: Molehill or mountain?
|
|
Academic Article
|
Branched-chain amino acids as pharmacological nutrients in chronic liver disease.
|
|
Academic Article
|
Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition.
|
|
Academic Article
|
The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
|
|
Academic Article
|
Nutritional status of patients with alcoholic cirrhosis undergoing liver transplantation: time trends and impact on survival.
|
|
Academic Article
|
Impact of obesity on treatment of chronic hepatitis C.
|
|
Academic Article
|
Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C.
|
|
Academic Article
|
Aquaporin-1 facilitates angiogenic invasion in the pathological neovasculature that accompanies cirrhosis.
|
|
Academic Article
|
Lumican, an extracellular matrix proteoglycan, is a novel requisite for hepatic fibrosis.
|
|
Academic Article
|
Genotype 1b and severity of posttransplant recurrence of hepatitis C infection- unconvictable felon or wrongly accused?
|
|
Academic Article
|
Fatty liver and liver transplantation.
|
|
Academic Article
|
Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
|
|
Academic Article
|
Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
|
|
Academic Article
|
Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes.
|
|
Academic Article
|
Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon.
|
|
Academic Article
|
Ultrasound-based transient elastography for the detection of hepatic fibrosis in patients with recurrent hepatitis C virus after liver transplantation: a systematic review and meta-analysis.
|
|
Academic Article
|
Neuropilin-1 promotes cirrhosis of the rodent and human liver by enhancing PDGF/TGF-beta signaling in hepatic stellate cells.
|
|
Academic Article
|
Treatment of HCV prior to liver transplantation to prevent HCV recurrence - wise or wasteful?
|
|
Academic Article
|
Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
|
|
Academic Article
|
Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.
|
|
Academic Article
|
On-treatment HCV RNA in patients with varying degrees of fibrosis and cirrhosis in the SOLAR-1 trial.
|
|
Academic Article
|
Liver Transplantation for Alcoholic and Nonalcoholic Fatty?Liver?Disease: Pretransplant Selection and Posttransplant?Management.
|
|
Academic Article
|
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
|
|
Academic Article
|
Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
|
|
Academic Article
|
A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition.
|
|
Academic Article
|
Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension.
|
|
Academic Article
|
Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
|
|
Academic Article
|
International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates.
|
|
Academic Article
|
International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Recipients.
|
|
Academic Article
|
Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
|
|
Academic Article
|
Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib.
|
|
Academic Article
|
Class III obesity is a risk factor for the development of acute-on-chronic liver failure in patients with decompensated cirrhosis.
|
|
Academic Article
|
The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial.
|
|
Academic Article
|
GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease.
|
|
Academic Article
|
Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral Therapy?for Hepatitis C Virus Infection.
|
|
Academic Article
|
Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
|
|
Academic Article
|
The Triumph of Bacchus: The Emergence of Nonalcoholic Steatohepatitis and Alcoholic Liver Disease as the Leading Causes of Mortality From Cirrhosis.
|
|
Academic Article
|
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
|
|
Academic Article
|
Knockout of sulfatase 2 is associated with decreased steatohepatitis and fibrosis in a mouse model of nonalcoholic fatty liver disease.
|
|
Academic Article
|
Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study.
|